![CANCER CAN SPREAD AFTER RADICAL PROSTATECTOMY By](http://s1.studyres.com/store/data/000097122_1-52430bc6094172ec03003b26073c6fbe-300x300.png)
CANCER CAN SPREAD AFTER RADICAL PROSTATECTOMY By
... can be left behind resulting in a "positive margin". Doctors can predict ahead of time the chances of a positive margin before surgery is performed, thus avoiding unnecessary surgery and its side effects. A predictive tool called the Partins Table, is used which combines the cancer stage, Gleason Sc ...
... can be left behind resulting in a "positive margin". Doctors can predict ahead of time the chances of a positive margin before surgery is performed, thus avoiding unnecessary surgery and its side effects. A predictive tool called the Partins Table, is used which combines the cancer stage, Gleason Sc ...
determination of CB 1 receptor binding and agonist activity of
... July 9, 2012, which is the most recent attempt by the United States government to control synthetic drugs, including cannabinoids. This legislation places synthetic cannabinoids into Schedule I of the Controlled Substances Act (21 U.S.C. 812(c)) based on structure, receptor binding, and function. Th ...
... July 9, 2012, which is the most recent attempt by the United States government to control synthetic drugs, including cannabinoids. This legislation places synthetic cannabinoids into Schedule I of the Controlled Substances Act (21 U.S.C. 812(c)) based on structure, receptor binding, and function. Th ...
Phase 3 studies of enobosarm
... This presentation and our remarks based upon it, including responses to questions made during and following the presentation, may include forward-looking statements. Such statements are subject to the risks and uncertainties we discuss in detail in our reports filed with the Securities & Exchange Co ...
... This presentation and our remarks based upon it, including responses to questions made during and following the presentation, may include forward-looking statements. Such statements are subject to the risks and uncertainties we discuss in detail in our reports filed with the Securities & Exchange Co ...
PRODUCT INFORMATION
... all cases. Chronic androgen deficiency is a protective factor for prostatic disease and hypogonadal men receiving androgen replacement therapy require surveillance for prostate disease similar to that recommended for eugonadal men of comparable age. Geriatric patients treated with androgens may be a ...
... all cases. Chronic androgen deficiency is a protective factor for prostatic disease and hypogonadal men receiving androgen replacement therapy require surveillance for prostate disease similar to that recommended for eugonadal men of comparable age. Geriatric patients treated with androgens may be a ...
ppt
... [LR] Rate of reaction proportional to [ ] reactants K1=[L]*[R] K2=[LR] At equilibrium, k1=k2. Substituting, k1/k2=[L]*[R]/[LR]=kD, the equilibrium dissociation constant ...
... [LR] Rate of reaction proportional to [ ] reactants K1=[L]*[R] K2=[LR] At equilibrium, k1=k2. Substituting, k1/k2=[L]*[R]/[LR]=kD, the equilibrium dissociation constant ...
Screening for Hormone-Like Therapeutic Compounds.pdf
... Background - Approximately 4% of the drug targets of current therapies belong to the nuclear hormone receptor superfamily. These transcription factors control the expression of several genes in response to the presence of small-molecule hormones or hormone-like compounds, and include the estrogen, a ...
... Background - Approximately 4% of the drug targets of current therapies belong to the nuclear hormone receptor superfamily. These transcription factors control the expression of several genes in response to the presence of small-molecule hormones or hormone-like compounds, and include the estrogen, a ...
PG12-12 Mairs Lay summary Principal Investigator: Dr Rob Mairs
... selectively binds to a prostate-specific marker (PSMA) expressed on prostate cancer cells that have spread (metastatic). This radiopharmaceutical (radiolabelled drug) has anti-tumour activity as a single agent. However, it is likely that its effectiveness will be significantly enhanced by combinatio ...
... selectively binds to a prostate-specific marker (PSMA) expressed on prostate cancer cells that have spread (metastatic). This radiopharmaceutical (radiolabelled drug) has anti-tumour activity as a single agent. However, it is likely that its effectiveness will be significantly enhanced by combinatio ...
CCO Formulary Data Sheet on Androcur
... Side effects are rarely of sufficient severity to require dosage reduction or discontinuation of treatment. The most common side effects are hormonal with changes in libido, breast tenderness and gynecomastia and impotence, which are reversible. Hepatotoxicity, including liver failure has been repor ...
... Side effects are rarely of sufficient severity to require dosage reduction or discontinuation of treatment. The most common side effects are hormonal with changes in libido, breast tenderness and gynecomastia and impotence, which are reversible. Hepatotoxicity, including liver failure has been repor ...
PG12-23 Falasca Lay summary Principal Investigator: Professor
... To develop new and more active drugs to oppose prostate cancer development and progression we need to understand which molecules are important for the tumour to grow. Once we identify these molecules, we can design drugs to block them and therefore block tumour growth. We have identified two molecul ...
... To develop new and more active drugs to oppose prostate cancer development and progression we need to understand which molecules are important for the tumour to grow. Once we identify these molecules, we can design drugs to block them and therefore block tumour growth. We have identified two molecul ...
Model Description Sheet
... (GPCRs) that undergo conformational changes when a ligand such as opium or morphine binds to it, initiating a downstream effect that ultimately relieves pain. If scientists can understand the molecular interactions when drugs bind these receptors, they can begin to develop a drug that binds these re ...
... (GPCRs) that undergo conformational changes when a ligand such as opium or morphine binds to it, initiating a downstream effect that ultimately relieves pain. If scientists can understand the molecular interactions when drugs bind these receptors, they can begin to develop a drug that binds these re ...
estrogens & androgens
... 1 - An 80-yr old woman with a history of acute MI & CHF presents to the ER Dept with a chief complaint of fever and lethargy. After a full workup a urinalysis is performed, yielding a specimen with a pH 5.5 & increased NaCl, K, & Ca concentrations. Which of the following drugs would cause results co ...
... 1 - An 80-yr old woman with a history of acute MI & CHF presents to the ER Dept with a chief complaint of fever and lethargy. After a full workup a urinalysis is performed, yielding a specimen with a pH 5.5 & increased NaCl, K, & Ca concentrations. Which of the following drugs would cause results co ...
estrogens and androgens
... Bone: agonist to prevent bone resorption Breast: antagonist Endometrium: a partial agonist with the risk of increasing endometrial cancer • USES: estrogen dependent breast cancer • SE: Hot flushes, nausea and vomiting ...
... Bone: agonist to prevent bone resorption Breast: antagonist Endometrium: a partial agonist with the risk of increasing endometrial cancer • USES: estrogen dependent breast cancer • SE: Hot flushes, nausea and vomiting ...
Discovery and development of antiandrogens
![](https://commons.wikimedia.org/wiki/Special:FilePath/Androgen_receptor.png?width=300)
In the 1960s, the first antiandrogen, or androgen antagonist, was discovered. Antiandrogens antagonise the androgen receptor (AR) and thereby block the biological effects of testosterone and dihydrotestosterone (DHT). Antiandrogens are important for men with hormonally responsive diseases like prostate cancer, benign prostatic hyperplasia (BHP), acne, seborrhea, hirsutism and androgen alopecia. Antiandrogens are mainly used for the treatment of prostate diseases. Research from 2010 suggests that ARs could be linked to the disease progression of triple-negative breast cancer and that antiandrogens can potentially be used to treat it.As of 2010 antiandrogens are small molecules and can be either steroidal or nonsteroidal depending on ligand chemistry. Steroidal antiandrogens share a similar steroid structure, while nonsteroidal antiandrogens may have structurally distinctive pharmacophores. Only a limited number of compounds are available for clinical use despite the fact that a very large variety of antiandrogen compounds have been discovered and researched.